Phase 2 Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination With AMG 386 as First Line or Second Line Therapy for Subjects With Metastatic Renal Cell Carcinoma

Trial Profile

Phase 2 Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination With AMG 386 as First Line or Second Line Therapy for Subjects With Metastatic Renal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Sunitinib (Primary) ; Trebananib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 02 Oct 2017 Planned End Date changed from 29 Sep 2017 to 29 Mar 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 01 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top